What is Medherant?
Medherant is a specialized biotechnology firm focused on the innovation of sustainable, patient-centric transdermal patches. By leveraging its proprietary TEPI Patch platform, the company addresses critical gaps in traditional drug delivery, offering enhanced comfort and convenience for long-term treatment regimens. The firm occupies a unique market position at the intersection of pharmaceutical innovation and medical device engineering, actively seeking strategic partnerships to scale its topical delivery systems. Their commitment to improving patient outcomes through advanced material science positions them as a key player in the evolving landscape of non-invasive therapeutic administration.
How much funding has Medherant raised?
Medherant has raised a total of $17.7M across 6 funding rounds:
Angel/Seed
$1.9M
Multiple Rounds
$9.5M
Corporate Investment
$2.5M
Other Financing Round
$3.8M
Angel/Seed (2016): $1.9M with participation from Mercia Technologies
Series A (2017): $2M led by Mercia Technologies PLC.
Private Equity (2017): $4.8M supported by Mercia Technologies PLC
Angel/Seed (2017): $2.7M featuring Mercia Technologies PLC. and Mercia Fund Management
Corporate Investment (2019): $2.5M backed by Mercia Technologies
Other Financing Round (2023): $3.8M, investors not publicly disclosed
Key Investors in Medherant
Mercia Technologies
Mercia Asset Management provides equity and debt financing to UK businesses with growth ambitions, acting as investment partners from scale-up to exit.
Mercia Fund Management
Mercia Fund Management Ltd is a company that operates in the Venture Capital and Private Equity industry, focusing on high-growth potential enterprises.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Medherant?
With this major enterprise-level funding, Medherant is well-positioned to transition from its current development phase toward broader commercialization and clinical validation. The strategic roadmap focuses on expanding the application of the TEPI Patch technology across diverse therapeutic areas, including complex CNS conditions. By prioritizing collaborative development agreements, the company aims to integrate its delivery systems into existing pharmaceutical portfolios, thereby maximizing the reach and efficacy of its proprietary technology. Future growth will likely be defined by the successful navigation of regulatory pathways and the scaling of manufacturing capabilities to meet anticipated market demand for high-performance transdermal solutions.
See full Medherant company page
